captopril has been researched along with exenatide in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Adams, L; Baron, AD; Broyde, A; Fernandez, R; Liu, Q; Parkes, DG | 1 |
1 review(s) available for captopril and exenatide
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for captopril and exenatide
| Article | Year |
|---|---|
The exenatide analogue AC3174 attenuates hypertension, insulin resistance, and renal dysfunction in Dahl salt-sensitive rats.
Topics: Animals; Antihypertensive Agents; Blood Glucose; Captopril; Cardiotonic Agents; Drug Therapy, Combination; Exenatide; Glucagon-Like Peptide 1; Hyperglycemia; Hypertension, Renal; Hypoglycemic Agents; Insulin Resistance; Kidney Diseases; Male; Peptides; Rats; Rats, Inbred Dahl; Sodium Chloride, Dietary; Venoms | 2010 |